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Toxin-antitoxin systems play key roles in bacterial adaptation, including protection from antibiotic 22 
assault and infection by bacteriophages. The type IV toxin-antitoxin system AbiE encodes a DUF1814 23 
nucleotidyltransferase-like toxin, and a two-domain antitoxin. In Streptococcus agalactiae, the 24 
antitoxin AbiEi negatively autoregulates abiE expression through positively co-operative binding to 25 
inverted repeats within the promoter. The human pathogen Mycobacterium tuberculosis encodes 26 
four DUF1814 putative toxins, two of which have antitoxins homologous to AbiEi. One such M. 27 
tuberculosis antitoxin, named Rv2827c, is required for growth and whilst the structure has 28 
previously been solved, the mode of regulation is unknown. To complete the gaps in our 29 
understanding, we first solved the structure of S. agalactiae AbiEi to 1.83 Å resolution for 30 
comparison with M. tuberculosis Rv2827c. AbiEi contains an N-terminal DNA binding domain and C-31 
terminal antitoxicity domain, with bilateral faces of opposing charge. The overall AbiEi fold is similar 32 
to Rv2827c, though smaller, and with a 65º difference in C-terminal domain orientation. We further 33 
demonstrate that, like AbiEi, Rv2827c can autoregulate toxin-antitoxin operon expression. In 34 
contrast to AbiEi, the Prv2827c promoter contains two sets of inverted repeats, which bind Rv2827c 35 
with differing affinities depending on the sequence consensus. Surprisingly, Rv2827c bound with 36 
negative co-operativity to the full Prv2827c promoter, demonstrating an unexpectedly complex form of 37 
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Toxin-antitoxin (TA) systems are encoded by genetic loci that are widely distributed throughout 46 
prokaryotic genomes. They can play pivotal roles in bacterial physiology and in managing stress 47 
responses, helping bacteria to survive nutrient limitation, immune system attack, antibiotic 48 
treatment and predation by bacteriophages [1–5]. TA systems are commonly found on mobile 49 
genetic elements, contributing to the stability of plasmids, superintegrons, cryptic prophages and 50 
conjugative transposons [6–8]. The majority of TA systems encode two components, a toxic protein 51 
that generally targets essential cellular processes, and an antagonistic antitoxin [4]. This antitoxin 52 
negates toxin activity when cells are growing in favorable conditions. Under stressful conditions, the 53 
antitoxin is preferentially degraded and the toxin is released, thereby reducing growth rate as a 54 
means to survive with minimal metabolic burden until favorable conditions return [9,10]. Activation 55 
of the toxin following bacteriophage infection can also lead to the removal of the infectious 56 
bacteriophage particle from the environment, thereby providing a population level protection from 57 
viruses referred to as abortive infection (Abi) [11,12]. 58 
 59 
TA systems have been divided into six types according to the nature of the toxin and antitoxin 60 
(whether they are RNA or protein), and the mechanism of toxin antagonism [4]. Type IV systems 61 
differ from all others in that the antitoxin and toxin do not directly interact, instead, the antitoxin 62 
antagonises the activity of the toxin [13–15]. There are multiple examples wherein TA systems 63 
provide a phage-resistant Abi phenotype, although not all identified Abi systems act as bona fide TA 64 
systems [5,15–20]. A recently characterised Abi system, AbiE from Streptococcus agalactiae V/R 65 
2603, has been shown to act as a type IV TA system [15]. AbiE encodes a DUF1814-family toxin 66 
(AbiEii), and a COG5340-family antitoxin (AbiEi) (Fig. 1A) [15]. The S. agalactiae AbiE COG5340 67 




specifically binds GTP [15]. This DUF1814 family is widespread, present in over 5,500 bacterial, 69 
archaeal and fungal genomes, though not all examples are genetically linked to putative antitoxins. 70 
 71 
TA systems are remarkably abundant in Mycobacterium tuberculosis, which encodes more than 80 72 
examples, and these are thought to have contributed to M. tuberculosis having become the most 73 
successful human pathogen [21–24]. M. tuberculosis H37Rv encodes four DUF1814-family NTase-like 74 
putative toxins, namely Rv0078A, Rv0836c, Rv1045 and Rv2826c (Fig. 1A). Akin to AbiEii from S. 75 
agalactiae, both Rv1045 and Rv2826c have a cognate COG5340-family antitoxin (Fig. 1A). 76 
Transposon mutagenesis studies have identified the cognate antitoxins of these systems (Rv1044 77 
and Rv2827c) as essential for lab growth [25,26], suggesting that Rv1045 and Rv2826c toxins are 78 
functional in M. tuberculosis. The M. tuberculosis COG5340 proteins will herein be referred to by 79 
their respective ‘Rv’ identifiers, Rv1044 and Rv2827c. Characterizing and understanding the 80 
regulation of these loci is of interest for developing new therapies against the pathogen. 81 
 82 
Autoregulation of TA system expression is a hallmark of type II TA systems and can be either positive 83 
or negative [27,28]. The antitoxin AbiEi from S. agalactiae has been biochemically characterized 84 
[15,29] and functions as both an antitoxin and a transcriptional repressor. That is, AbiEi negatively 85 
autoregulates abiE expression. Here, the gene product suppresses its own production, through 86 
positively co-operative binding of two AbiEi monomers to inverted repeats in the promoter region. 87 
Full length AbiEi is required for negative autoregulation and induced bending of the promoter DNA. 88 
We previously proposed that this bending was facilitated by the two AbiEi monomers interacting via 89 
their C-terminal domains (CTDs) [29]. In contrast to type II autoregulation, for which conditional co-90 
operativity is observed, co-expression of the cognate toxin AbiEii does not enhance transcriptional 91 




AbiEi and Rv2827c. While the structure of the M. tuberculosis putative antitoxin Rv2827c has been 93 
solved as part of a structural genomics initiative [30], its biological function was not explored and it 94 
has not been biochemically characterized. We present the solved structure of S. agalactiae AbiEi, 95 
demonstrating structural homology between the COG5340 antitoxins, and biochemically 96 
characterize the molecular interactions underpinning transcriptional repression by Rv2827c. 97 


















MATERIALS AND METHODS 113 
Bacterial strains and culture conditions 114 
E. coli DH5 (Invitrogen), BL21 (DE3) (Invitrogen) and ER2566 (New England Biolabs) were routinely 115 
grown at 37 °C in Luria-Broth (LB), M9 minimal (M9M), or 2x YT media supplemented when 116 
necessary with ampicillin (Ap, 50  μg/ml), spectinomycin (Sp, 100 g/ml), tetracycline (Tc, 10 µg/ml), 117 
isopropyl-β-D-thiogalactopyranoside (IPTG, 1 mM), L-arabinose (L-ara, 0.1% w/v) or D-glucose (glu, 118 
0.2% w/v). Bacterial cell density was measured using a WPA Biowave C08000 at 600 nm (OD600). 119 
 120 
DNA isolation and manipulation 121 
All oligonucleotides used in this study were obtained from Integrated DNA Technologies (Table S1). 122 
Plasmid and PCR-amplified DNAs were purified using Monarch kits (NEB). Digests, ligations, 123 
transformations and agarose gel electrophoresis steps were performed by standard techniques. All 124 
constructed plasmids (Table S2) were confirmed by sequencing using an ABI 3730 DNA sequencer 125 
and 4Peaks. 126 
 127 
Protein expression constructs were made by Ligation Independent Cloning (LIC) [31]. Target genes 128 
were cloned into plasmid pSAT1-LIC, which generates N-terminal His6-SUMO fusions with the target 129 
ORF. Primers TRB1048/TRB1049 were used to amplify abiEi from pRLD30, for LIC insertion into 130 
pSAT1-LIC, producing pTRB525. Primers TRB1022/TRB1023 were used to amplify rv2827c from 131 
pPF658, also for LIC insertion into pSAT1-LIC, producing pTRB493. Primers TRB1018/TRB1019 were 132 
used to amplify rv1044 from M. tuberculosis H37Rv genomic DNA (ATCC), again for LIC insertion into 133 





For promoter activity assays, regions upstream of abiEi, rv2827c and rv1044 were cloned into 136 
pRW50 [32]. The 99 bp region upstream of abiEi was amplified from pPF680 using primers 137 
TRB1072/TRB1047, then digested with EcoRI/HindIII and ligated into pRW50 cut with the same 138 
enzymes, producing pTRB486. The 500 bp regions upstream of rv2827c and rv1044 were amplified 139 
from H37Rv genomic DNA, using primers TRB1042/TRB1043 and TRB1040/TRB1041, respectively. 140 
The amplicons were digested with EcoRI/HindIII and ligated into pRW50 cut with the same enzymes, 141 
producing pTRB484 and pTRB483, respectively. Antitoxin genes abiEi, rv2827c and rv1044 were 142 
cloned into pTA100, a pQE-80 derivative [5]. S. agalactiae abiEi was amplified from pRLD30 using 143 
primers TRB1052/TRB1053 the digested with EcoRI/HindIII and ligated into pTA100 cut with the 144 
same enzymes, producing pTRB481. M. tuberculosis rv2827c and rv1044 were amplified from H37Rv 145 
genomic DNA, using primers PF1334/PF1335 and PF1330/PF1331 respectively. The amplicons were 146 
digested with NdeI/SpeI and ligated into pTA100 cut with the same enzymes, producing pPF658 and 147 
pPF658, respectively. 148 
 149 
Protein expression and purification 150 
To express AbiEi, Rv2827c and Rv1044 for crystallization and/or biochemistry, E. coli ER2566 (for 151 
native protein) or BL21 (DE3) (for labelled protein) were transformed with pTRB525, pTRB493 or 152 
pTRB491, respectively. For native protein, overnight cultures were re-seeded 1:100 into 2 L flasks 153 
containing 1 L 2x YT. Cells were grown at 150 rpm in 37 °C until an OD600 of 0.6-0.8 was reached, 154 
whereupon expression was induced by the addition of IPTG (1 mM). Cells were left to grow for 16 h 155 





For incorporation of selenomethionine into AbiEi, the SeMet kit (Molecular Dimensions) was used. 158 
Starter cultures of BL21 (DE3) pTRB525, starter cultures were grown for 8 hours in LB at 37 °C with 159 
200 rpm shaking. This culture was used to inoculate (1:500) a 50 mL overnight of Molecular 160 
Dimensions Selenomethionine Base medium supplemented with Molecular Dimensions Nutrient 161 
Mix. This overnight was then used to inoculate (1:100) 1 L of the same Base Medium with Nutrient 162 
Mix and cells were grown at 37 °C with 180 rpm shaking. At OD600 0.8 cells were pelleted by 163 
centrifugation at 4200 x g, resuspended in fresh Base Medium with Nutrient Mix (Molecular 164 
Dimensions) and supplemented with an amino acid mix to promote feedback inhibition of 165 
methionine synthesis (0.1 mg/ml L-lysine hydrate, 0.1 mg/ml L-threonine, 0.1 mg/ml L-166 
phenylalanine, 0.05 mg/ml L-leucine, 0.05 mg/ml L-isoleucine, 0.05 mg/ml L-valine). Cells were 167 
grown for a further 30 minutes at 37 °C with shaking at 180 rpm before the addition of 250x 168 
SelenoMethionine Solution (Molecular Dimensions) to a final concentration of 40 μg/mL. Cells were 169 
grown for a further 15 minutes at 37 °C with shaking at 180 rpm before antitoxin expression was 170 
induced with IPTG (1 mM), and samples were left to grow overnight at 175 rpm in 18 °C.  171 
 172 
For native protein purification, bacteria were harvested by centrifugation at 4200 x g and the pellets 173 
were resuspended in buffer A500 (20 mM Tris-HCl pH 7.9, 500 mM NaCl, 5 mM imidazole and 10% 174 
glycerol). Cells were lysed by sonication at 40 kpsi, then centrifuged (45,000 x g, 4 °C). The clarified 175 
lysate was next passed over a HisTrap HP column (GE Healthcare), washed for ten column volumes 176 
with A500, followed by ten column volumes of buffer A100 (20 mM Tris-HCl pH 7.9, 100 mM NaCl, 5 177 
mM imidazole and 10% w/v glycerol), then eluted directly onto a HiTrap Q HP column (GE 178 
Healthcare) with buffer B100 (20 mM Tris-HCl pH 7.9, 100 mM NaCl, 250 mM imidazole and 10% w/v 179 
glycerol). The Q HP column was transferred to an Äkta Pure (GE Healthcare), washed with three 180 
column volumes of A100, then proteins were eluted using a gradient from 100% A100 to 100% 181 




protein peak were analysed by SDS-PAGE, pooled and incubated overnight at 4 °C with hSENP2 183 
SUMO protease to cleave the His6-SUMO tag from the target protein. The following day, the samples 184 
were passed through a second HisTrap HP column and the flow-through fractions containing 185 
untagged target protein were collected. The same procedure was used for labelled protein, except 186 
seleno-AbiEi precipitated on column at A100, contaminants were removed with B100, and remaining 187 
folded seleno-AbiEi was eluted with B500, followed by SENP cleavage and a second HisTrap column 188 
purification. Proteins were dialysed overnight at 4 °C into buffer X (20 mM Tris-HCl pH 7.9, 200 mM 189 
NaCl and 2.5 mM DTT). Crystallization samples were concentrated, quantified and stored on ice, 190 
then either used immediately or flash-frozen in liquid N2 for storage at -80 °C. 191 
 192 
Protein crystallization 193 
Native and selenomethionine-derivatized AbiEi were concentrated to 12 mg/ml in buffer X (see 194 
above). Initial native AbiEi crystallization screens were performed using commercial screens 195 
(Molecular Dimensions) set with an Innovadyne Screenmaker robot, making 200:100 nl and 100:100 196 
nl protein:condition sitting drops at 18 ºC. After initial screening and optimization, native AbiEi 197 
formed thick needles in 0.02 M Sodium/Potassium phosphate, 0.1 M Bis-Tris Propane pH 6.5, 20% 198 
PEG 3350. Selenomethionine-derivatized AbiEi crystals grew in 0.2 M Sodium acetate trihydrate, 0.1 199 
M Bis-Tris Propane pH 6.5, 15% PEG 3350. To harvest, 20 µl of condition reservoir was added to 20 µl 200 
of glycerol and mixed quickly by vortexing; an equal volume of this mixture was then added to the 201 
drop volume. After addition of cryo buffer, crystals were immediately extracted using a nylon loop 202 
and flash-frozen in liquid N2. 203 
 204 




Diffraction data were collected at Diamond Light Source on beamlines I03 (AbiEi native) and I03 206 
(AbiEi selenomethionine-derivatized) (Table 1). Single, 360°, datasets were collected from three 207 
native AbiEi crystals and merged using iSpyB (Diamond Light Source). Two, 360°, datasets from AbiEi 208 
selenomethionine-derivatized crystals measured at the selenium peak (0.9793 Å) were also merged 209 
using iSpyB. An additional AbiEi selenomethionine-derivatized dataset was collected at selenium 210 
high remote (0.9641 Å) wavelength. Diffraction data were processed with XDS [33,34], and then 211 
AIMLESS from CCP4 [35] was used to corroborate the spacegroups (Table 1). The crystal structure of 212 
AbiEi was solved by MAD, by providing the SHELX suite [36] in CCP4 with the native, peak and high 213 
remote datasets. The solved starting model for AbiEi was built in REFMAC [37] and BUCCANEER [38]. 214 
The model was then iteratively refined and built using PHENIX [39] and COOT [40], respectively. The 215 
quality of the final model was assessed using COOT and the wwPDB validation server [41]. Structural 216 
figures were generated using PyMol (Schrödinger). Structural alignments were performed using 217 
PROMALS3D [42]. 218 
 219 
Electrophoretic Mobility Shift Assays 220 
Conservation of IR sequences was determined using MView [43] and WebLogo [44]. Promoter region 221 
probes were amplified from synthesised templates (Table S1). Each template was made with a 222 
common downstream region, matching the initial part of lacZ from pRW50. For each probe 223 
template, a unique upstream forward primer was used in combination with a common reverse 224 
primer, which was either untagged or had been conjugated to a fluorescein tag for visualization 225 
(Table S1). The probes contained either the native promoter regions, or combinations of WT IR 226 





Proteins were diluted to appropriate concentrations using diluent buffers matching their storage 229 
buffer constitution. Each binding reaction contained 2 µL of 5x EMSA binding buffer (750 mM KCl, 50 230 
mM Tris-HCl pH 8.0, 2.5 mM EDTA pH 8.0, 0.5 % Triton X-100, 1 mM DTT, 55% glycerol), 250 fmoles 231 
of fluorescently labelled probe, 0.1 µL BSA (10 mg/ml), 1 µL poly(d[IC]) (1 mg/mL), 1 µL of diluted 232 
protein or buffer control and water to a final volume of 10 µL. Native 0.5x TBE polyacrylamide gels 233 
(at either 7% or 5% acrylamide, as required) were pre-run at 150 V and 4 ºC for 2 h. Binding reactions 234 
were titrated at protein concentrations from zero to an appropriate upper limit, and incubated at 20 235 
ºC for 30 min. Non-specific binding controls used an additional excess of 2.5 µM  TRB1108 template 236 
DNA amplified with TRB1109 as forward primer, and non-labelled reverse primer. Specific binding 237 
controls used additional excess of 2.5 µM unlabelled specific probe DNA. Samples were then 238 
separated by native polyacrylamide gel electrophoresis at 200 V and 4 ºC for 45 min.  239 
 240 
Native polyacrylamide gels were then visualised using the Amersham Biosciences Typhoon 9400 on 241 
variable mode image in fluorescence mode, emission filter 526 SP. Sensitivity was set to normal. 242 
Band intensities were calculated using the grid scan feature and triplicate data processed in Prism 243 
(GraphPad Software). Fractional saturation curves were produced with fractional saturation, Y, 244 
varying from 0 – 1.0. Y values are calculated by (Y/(Y+(1-Y))) and plotted against protein 245 
concentration. Data were converted to the Hill plot to analyse the degree of cooperativity in the 246 
binding events, characterised by the Hill coefficient (slope of the plot at log(θ)=0). The Hill plot is 247 
constructed by plotting logθ against log[protein], with θ defined as (θ = (Y/(1-Y))). Dissociation 248 
coefficients (Kd) can also be extracted from the Hill plot as Kd = 10X-intercept. Mean and standard error 249 
of the mean values are derived from at least three independent experiments. 250 
 251 




Promoter regions were cloned into the promoterless lacZ fusion plasmid, pRW50 [32]. Antitoxin 253 
genes were cloned into the pQE-80 derivative, pTA100 [5] for tight control of antitoxin expression. 254 
Construction is detailed above. Promoter activity assays were performed as described previously 255 
[45,46]. Briefly, E. coli DH5α were co-transformed with the lacZ reporter constructs pTRB483 (Prv1044), 256 
pTRB484 (Prv2827c) or pTRB486 (PabiEi), and the IPTG-inducible pTA100-antitoxin plasmids pPF656 257 
(Rv1044), pPF658 (Rv2827c) or pTRB481 (AbiEi). Transformants were re-seeded from overnight 258 
cultures and grown in 37 °C at 200 rpm in LB supplemented with Tc, Sp, and with/without IPTG until 259 
mid-log phase, then 80 µl of cells were added to 120 µl master mix (60 mM Na2HPO4, 40 mM 260 
NaH2PO4, 10 mM KCl, 1 mM MgSO4, 36 mM β-mercaptoethanol, 166 μl/ml T7 lysozyme, 1.1 mg/ml 261 
ONPG, and 6.7 % PopCulture Reagent (Merck Millipore)) in corresponding wells of a 96-well plate. 262 
This was then placed in a SPECTROstar Nano absorbance plate reader (BMG LABTECH) set to 30 °C 263 
with shaking at 500 rpm, wherein OD600 and OD420 readings were taken every 90 seconds for 1 hour. 264 
Data analysis was performed in the MARS Data Analysis software package (BMG LABTECH). The 265 
kinetic OD420 readings were converted into the slope of OD420 over time (OD420/min). These values 266 
were multiplied by 5000 and divided by the OD600 reading from the first time point to generate 267 
Miller Units (mU). Plotted data are the normalized mean and standard deviation obtained from 268 
three independent experiments. 269 
 270 
 271 
Accession number 272 
The crystal structure of AbiEi has been deposited in the Protein Data Bank under accession number 273 
6Y8Q. 274 





AbiEi-family antitoxins contain conserved structural features 277 
We had previously hypothesized that there was structural similarity between the biochemically 278 
characterised antitoxin AbiEi from S. agalactiae [29] and the structurally characterised homologue, 279 
Rv2827c [30]. We sought to confirm structural and biochemical similarity between these two 280 
proteins, and within the broader COG5340 antitoxins. To begin, we solved a 1.83 Å structure of AbiEi 281 
by X-ray crystallography (Figs. 1B and C, Table 1). There were four copies of AbiEi in the asymmetric 282 
unit, forming minor crystal contacts that are not predicted to be biologically relevant, and each copy 283 
contains minor variations in domain orientation, indicating some flexibility. Together with previous 284 
size exclusion chromatography data [29], we concluded that AbiEi is a 23 kDa monomer in solution. 285 
 286 
AbiEi contains an N-terminal winged helix-turn-helix DNA-binding domain and a C-terminal antitoxin 287 
domain, connected by a short linker (Fig. 1B). Mutagenesis studies have demonstrated that full-288 
length AbiEi is required for negative autoregulation of the PabiE promoter, whilst the C-terminal 289 
domain alone is sufficient for antitoxicity against the effects of AbiEii [15]. The N-terminal domain 290 
contains three α-helices, followed by three beta-strands forming an antiparallel sheet (Fig. 1B). The 291 
C-terminal domain begins with a single α-helix that is separated from a six-helix bundle by a row of 292 
four β-strands, which themselves pair into parallel and antiparallel β-sheets (Fig. 1B). One face of 293 
AbiEi is positively charged, and the reverse face is negatively charged (Fig. 1C). The positive side 294 
corresponds with the site of positively charged sidechains distributed throughout the N-terminal and 295 
C-terminal domains, which have previously been shown to be vital for DNA-binding and 296 
autoregulation through mutagenesis studies [29]. When AbiEi is compared with Rv2827c, both are 297 
monomers and it is clear that the two antitoxins share the two-domain structure and charge 298 





When AbiEi and Rv2827c are aligned via the N-terminal winged helix-turn-helix domain, the 301 
respective C-terminal domains differ in position relative to the N-terminal domains by approximately 302 
65º (Fig. 2A). We propose that these different poses captured in the crystal structures might reflect 303 
variable positions of the C-terminal domains potentially allowed by a linker joining the two domains. 304 
The stability of the B-factors for the subdomains AbiEi and Rv2827c, alongside lack of significant 305 
variation in the domain orientations within the asymmetric unit indicates a preferred state has been 306 
captured in the crystal. This however would require further analysis in solution.  The extensive 307 
nature of the AbiEi charged surface, the requirement for the full AbiEi protein for autoregulation 308 
[15], and the presence of a flexible linker altogether indicate the full protein is needed for DNA 309 
interactions and DNA bending as per our previously proposed model [29].  310 
 311 
When the N-terminal domain helices and C-terminal domains from AbiEi and Rv2827c are separated 312 
and structurally superposed, it is possible to see an approximate overlay between corresponding 313 
regions, with RMSDs of 3.04 Å for the N-terminal helices and 3.41 Å for the C-terminal domains (Fig. 314 
2B and C). The N-terminal domains have conserved positioning of key helices H2 and H3, which are 315 
used within winged helix-turn-helix domains for stabilization and DNA recognition, respectively [47] 316 
(Fig. 2B). The C-terminal domain of AbiEi is the smaller of the two; performing a structure-based 317 
sequence alignment of AbiEi and Rv2827c shows that Rv2827c has an extended C-terminal domain 318 
55 amino acids longer than AbiEi (Fig. S1). Despite this extension, AbiEi and Rv2827c share a 319 
conserved common core fold of unknown function (Fig. 2C). When AbiEi was compared against the 320 
PDB to look for similar structures, using the DALI server [48], Rv2827c was the top hit followed by 321 
bacterial antibiotic-modifying adenylyltransferases (PDB codes 5KQJ, 4FO1), and a putative fungal 322 




activity of the cognate toxin AbiEii [15]. Overall, despite differing captured poses and discrepancy in 324 
size, AbiEi and Rv2827c are markedly similar in domain structure, fold and surface charge and are 325 
therefore structural homologues.  326 
 327 
It has been shown that the AbiEi C-terminal domain is required for negative autoregulation and likely 328 
contributes to positive cooperativity through C-terminal domain interactions [29]. The cons-PPISP 329 
server [49] was used to highlight the residues most likely to be critical for protein-protein 330 
interactions for both AbiEi and Rv2827c (Fig. 2D-E). In the AbiEi monomer, 16 identified residues 331 
were clustered at the C-terminus, forming a putative site for interaction (Fig. 2D). For Rv2827c, 332 
however, the diffuse scattering of 34 identified residues along the structure (Fig. 2E) predicts that 333 
there may be no obvious interface for protein-protein interactions. This is reinforced by the different 334 
positioning of the CTD seen in Rv2827c (Fig 2A). These findings suggest that the interactions of AbiEi 335 
C-terminal domains could contribute to positive co-operativity in promoter binding, supporting our 336 
previously proposed model, whereas for Rv2827c, such interactions are unlikely to occur and 337 
indicate a different mechanism of DNA-binding and autoregulation. 338 
    339 
Rv2827c binds two sets of inverted repeats 340 
AbiEi binds to two 23 bp inverted repeats (IR1 and IR2) within the promoter of PabiEi, which are 341 
separated by 3 bp [29] (Fig. 3A). Examination of the upstream region of Prv2827c revealed two pairs of 342 
23 bp inverted repeats within the region -1 to -131 bp from the rv2827c start codon, that also 343 
overlap the promoter (Fig. 3A). These four repeats (IR1 to IR4) are arranged in tandem with a 4 bp 344 
gap between the two pairs of inverted repeats and a 13 bp gap between the repeats within each pair 345 
(Fig. 3A). As PabiEi repeats are separated by 3 bp and the repeats within pairs from Prv2827c are 346 




terminal domains of Rv2827c (Fig. S1). Using the bacterial promoter prediction software 348 
CNNPromoter_b [50], the IR3-IR4 repeats were predicted to straddle a binding site for the primary 349 
M. tuberculosis sigma factor SigA [51]. As Rv2827c binding would sterically hinder sigma factor 350 
binding, in turn, this would prevent transcription of the operon by RNA polymerase. When IR1-IR4 351 
sequences from Prv2827c were aligned with IR1-IR2 sequences from PabiEi, the sequence similarity 352 
indicated possible conservation of binding sequence (Fig. 3B). We therefore hypothesized that 353 
despite sharing low protein sequence identity (17.7%), Rv2827c might bind these Prv2827c inverted 354 
repeats similarly to AbiEi binding its cognate PabiEi repeats. 355 
 356 
The four Prv2827c 23 bp inverted repeats were first tested as two consecutive pairs, to allow a direct 357 
comparison to the arrangement of PabiEi [29]. Analysis began with IR3-IR4, the pair overlapping the 358 
transcriptional start and therefore analogous to IR1-IR2 of PabiEi (Fig. 4A). Using electrophoretic 359 
mobility shift assays (EMSAs), Rv2827c was shown to bind both of the IR3-IR4 inverted repeats 360 
within the -1 to -71 region (Fig. 4B). Sequential removal of the inverted repeats by mutating one, the 361 
other or both to poly-C tracts reduced Rv2827c-DNA interaction to a single binding event (Fig. 4C 362 
and D) or ablated binding completely (Fig. 4E). Analysis of IR3-IR4 binding (Fig. 4B and F) showed 363 
weak saturation of binding. The calculated Hill co-efficient indicates that IR3-IR4 binding by Rv2827c 364 
is not co-operative (Fig. 4G).  365 
 366 
Similar results were obtained when testing the IR1-IR2 repeats within the -61 to -131 region of 367 
Prv2827c (Fig. 5A-G). In this case, there was greater saturation of binding to IR1-IR2 (Fig. 5F) than to 368 
IR3-IR4 (Fig. 4F). The Hill co-efficient surprisingly indicated weakly negative co-operativity in Rv2827c 369 
binding to IR1 and IR2 (Fig. 5G), in comparison to the non-co-operative binding observed with IR3 370 




assays with purified AbiEi and probes for PabiEi (Fig. S2). This corroborated previous data [29] and 372 
under our experimental conditions, AbiEi bound more tightly to its cognate inverted repeats (Fig. 373 
S2F), than either Rv2827c binding to IR3-IR4 (Fig. 4F) or IR1-IR2 (Fig. 5F), and also demonstrated 374 
clear positive co-operativity (Fig. S2G). 375 
 376 
Due to similarity of structure, functionality and cognate DNA inverted repeat sequences, we 377 
hypothesized that AbiEi and Rv2827c might bind their respective non-cognate promoter regions. 378 
However, AbiEi did not bind either pair of inverted repeats from Prv2827c (Fig. S3A and B). Similarly, 379 
Rv2827c did not bind IR1-IR2 of PabiEi (Fig. S3C).  380 
 381 
Rv2827c binds with negative co-operativity 382 
Having investigated the two sets of Prv2827c inverted repeats independently, a full-length probe 383 
covering the Prv2827c region -1 to -131 was generated to examine the interaction of Rv2827c protein 384 
with all four inverted repeats. Using EMSAs, four distinct protein-bound DNA species were observed, 385 
indicating that all four inverted repeats can be bound simultaneously by Rv2827c (Fig. 6A). The four 386 
binding sites did not fully saturate (Fig. 6B), and the Hill coefficient confirmed negatively co-387 
operative binding of Rv2827c across these four inverted repeats (Fig. 6C). Displaying the saturation 388 
curve data on a semi-log scale highlights breaks and multiple distinct gradients in the binding curve, 389 
eluding to multiple individual binding events (Fig. 6D). Negatively co-operative binding by Rv2827c 390 
to Prv2827c contrasts with the positive co-operativity observed for AbiEi binding to PabiEi [29].  391 
 392 
Our earlier data using mutant probes provided insight into how Rv2827c binds to individual repeats 393 




individual IR sequence, with IR1 most tightly bound (Kd of 0.0205 µM), closely followed by IR4 (Kd of 395 
0.121 µM), then IR2 (Kd of 0.862 µM), and finally IR3 (Kd of 11.0 µM) (Fig. 6E-M). This descending 396 
affinity series creates a wide range of concentrations across which negative autoregulation by 397 
Rv2827c can occur. These data demonstrate the same core principles of promoter binding are used 398 
by both AbiEi and Rv2827c, but that these have been employed evolutionarily for differing modes of 399 
regulation. 400 
 401 
Rv1044 is a DNA-binding protein, but fails to recognize the cognate 402 
promoter 403 
Whilst it had not been possible to identify inverted repeats within the rv1044-rv1045 locus, two, 404 
slightly overlapping, 70 bp probes were generated to cover the 131 bp region upstream of the 405 
rv1044 translational start site, and used to test Rv1044 binding (Fig. S4A and B). No binding event 406 
was observed with either probe (Fig. S4A and B). Nevertheless, we wanted to test whether Rv1044 407 
was competent for DNA-binding and so cross-reacted Rv1044 with the two probes covering IR3-IR4 408 
and IR1-IR2 of Prv2827c, and the probe containing IR1-IR2 of PabiEi (Fig. S4C, D and E). No binding was 409 
observed for either of the Prv2827c probes (Fig. S4C and D), but curiously, Rv1044 bound the inverted 410 
repeats of PabiEi (Fig. S4E). Rv1044 bound more weakly than AbiEi to PabiEi IR1-IR2 (Fig. S4F), and 411 
showed no co-operativity (Fig. S4G). This demonstrates that Rv1044 can bind DNA in a sequence-412 
specific manner, and so we looked for potential targets in the M. tuberculosis H37Rv genome. The 413 
abiE IR sequences align with numerous positions in the M. tuberculosis genome but not upstream of 414 
any of the DUF1814 TA systems. This may indicate a potential role for Rv1044 in regulating genes 415 
outside of the rv1044-rv1045 operon, as has been shown in other TA systems whereby antitoxins 416 
influence gene expression in biofilm formation pathways [52–54]. A further study will be needed to 417 





Rv2827c negatively autoregulates Rv2827c-Rv2826c expression 420 
Having shown a structural similarity between the two antitoxins, we next sought to test whether the 421 
COG5340 proteins from M. tuberculosis could function as autoregulators, like characterized AbiEi 422 
[29]. AbiEi negatively autoregulates expression from the PabiEi promoter [29]. To examine whether 423 
Rv2827c and also the second M. tuberculosis COG5340 protein, Rv1044, also perform negative 424 
autoregulation, we first cloned the 500 bp region upstream of each respective translational start site 425 
into a promoterless lacZ-reporter plasmid [32]. For comparison, the equivalent PabiEi–reporter, 426 
containing the previously identified promoter region identified in the upstream 99 bp [15,29] was 427 
also tested. Both PabiEi and Prv2827c reporters yielded expression of LacZ, but Prv1044 did not (Fig. 7A). 428 
The two active reporter constructs PabiEi and Prv2827c, were then paired with inducible plasmids for 429 
expression of the cognate antitoxins, and LacZ levels were determined with and without antitoxin 430 
induction (Fig. 7B). When compared to the uninduced controls, both antitoxins negatively 431 
autoregulated expression from their cognate promoters (Fig. 7B) demonstrating that Rv2827c and 432 
AbiEi share not only a common structure, but also a common negative autoregulatory function. 433 





In this study we present the crystal structure of S. agalactiae AbiEi, which was the first type IV TA 436 
system antitoxin shown to be capable of transcriptional autoregulation through promoter binding 437 
[29]. Further to this, we have demonstrated the autoregulatory capacity of the related Rv2827c 438 
antitoxin, a protein of known structure [30]. Whilst AbiEi is a structural homologue of the Rv2827c 439 
antitoxin, and both share similar promoter architectures, they have distinct differences in their size 440 
and captured domain orientations. We also show that negative autoregulation of the Prv2827c 441 
promoter operates via negatively co-operative interactions. 442 
 443 
Despite the low shared sequence similarity seen for the COG5349 antitoxins investigated (AbiEi and 444 
Rv2827c – 17.7 %; AbiEi and Rv1044 – 21.2 %; Rv2827c and Rv1044 – 24.5 %), we have 445 
demonstrated structural conservation across species. As sequences diverge, structure is conserved 446 
(Fig. 1, Fig. 2), which maintains the shared functionality of these antitoxins, for instance, DNA-447 
binding (Figs. 4–7, Figs. S2–S4). Interestingly, sequence variation of the NTD, alongside differing 448 
promoter architectures, has resulted in at least three variations of antitoxicity. AbiEi and Rv2827c 449 
both autoregulate their own operons, albeit with contrasting types of cooperativity. Rv1044, 450 
however, may regulate genes elsewhere in the M. tuberculosis genome, given the lack of affinity to 451 
the rv1044 upstream region tested (Fig. S4A-B) and absence of identifiable inverted repeats, but 452 
apparent DNA-binding capabilities (Fig. S4E-G). Further analysis will be required to identify a 453 
functional promoter for the rv1044-rv1045 operon and confirm any potential regulatory function of 454 
Rv1044. The antitoxic CTDs have a common core fold that are predicted to have NTase activity based 455 
on structure-based functional searches [30]. Therefore, the antitoxic mechanism is likely conserved, 456 
despite low sequence similarity within these domains (Fig. S1). As protein sequences will be tuned to 457 




protein-protein interactions (Fig. 2D-E) which, alongside the different CTD positions captured (Fig. 459 
2A), may contribute to individual autoregulation requirements. Our previous model predicted AbiEi 460 
C-terminal domain interactions promote positive co-operative binding and result in DNA-bending 461 
[29], however this does not appear to apply to Rv2827c. Our proposed model (Fig. 8) implies a 462 
possible lack of protein-protein interactions supported by predicted interaction interfaces (Fig. 2D-463 
E), while not ruling out the potential for steric restriction. Rather, promoter inverted repeat 464 
sequence ‘tuning’ (Fig. 3) contributes to the negatively co-operative interaction via descending 465 
affinities. 466 
 467 
Promoters of M. tuberculosis are known to be more complex than those of E. coli; they can stretch 468 
to 2000 bp from the start site and lack canonical elements such as the conserved -35 sequence [55–469 
57]. Transcriptional regulation is complicated further when considering the vast number of sigma 470 
factors [58] and environmentally responsive transcription factors [59] present in M. tuberculosis, 471 
allowing for greater promoter sequence variation. The -10 sequence for rv2827c-rv2826c is a 472 
predicted recognition site for principle M. tuberculosis sigma factor SigA, which is usually maintained 473 
at a constant level for cellular “housekeeping” [51]. SigA also has a role in host-pathogen 474 
interactions, controlling growth rates during macrophage infection [60] and regulating virulence 475 
genes through both constitutive and upregulated expression [61–63]. Deletions of rv2827c cause a 476 
growth defect [25,26], suggesting SigA drives expression and that there is potential for output to be 477 
tuned by SigA and Rv2827c levels according to environmental cues. Previous reports on the type IV 478 
antitoxin CbeA demonstrate a positive effect on cytoskeletal bundling alongside antitoxicity and the 479 
ability to counteract chemical inhibitors of cytoskeletal polymerisation [13]. One study has shown 480 
Rv2827c upregulation in response to isoniazid and rifampicin treatment, albeit as part of more 481 





The IR conservation between PabiEi and Prv2827c (Fig. 3) suggested that autoregulation may also occur 484 
in a biochemically comparable manner between the two. However, Rv2827c bound the pairs of 485 
inverted repeats with either no co-operativity (Fig. 4), or weakly negative co-operativity (Fig. 5). 486 
There was clear negative co-operativity when all four inverted repeats were tested (Fig. 6). Analysing 487 
each inverted repeat independently by mutational studies identified significant differences between 488 
the Rv2827c-IR dissociation constants (Fig. 6E-M). These data have allowed us to propose a model 489 
for the regulation of rv2827c-rv2826c (Fig. 8). As rv2827c is needed for normal growth, this suggests 490 
that rv2826c encodes a toxin capable of causing growth defects [25,65], which is antagonised by 491 
Rv2827c (Fig. 8A). Expression of rv2827c-rv2826c is negatively autoregulated by Rv2827c, and this is 492 
made possible by sequential binding of Rv2827c to the four IR sequences, in order as determined by 493 
binding affinity (Fig. 8B). Given the high concentration of Rv2827c required to saturate the lower 494 
affinity site IR3 (Fig. 6J, K; Fig. 8B), mimicking the mutational analysis performed here in promoter 495 
activity studies would provide useful insight into the function of each IR sequence. These binding 496 
events have apparent negative co-operativity, likely due to the variations in IR sequences creating a 497 
series of binding steps with ever-decreasing affinity. In order to better understand these negatively 498 
co-operative interactions further experiments are required, exploring the role of the Rv2827c CTD 499 
and increased inverted repeat spacers, akin to previous work on AbiEi [29].  500 
 501 
Negative cooperativity was an unexpected result given the structural similarities between the N-502 
terminal domains of AbiEi and Rv2827c (Fig. 2B), and the similarities of their respective promoter 503 
architectures (Fig. 3). Examples of negative and positive co-operativity have been found in equal 504 
abundance across all organisms [66,67]. Positive co-operativity leads to rapid saturation at a defined, 505 




binding would be expected to generate a relatively delayed response, working across a greater range 507 
of Rv2827c concentrations [67–69]. This variability in tuning according to concentration could in turn 508 
relate to the relative potency of the toxins and dosage required to have an effect in their cognate 509 
hosts. This variation is evident when comparing saturation curves of AbiEi and Rv2827c to their 510 
cognate full-length promoters (Fig. 6B and Fig. S2F). Compared to positive co-operativity, there is 511 
relatively little information on the presence of negatively co-operative TA-promoter interactions. 512 
However, clear evidence supports weaker binding of un-complexed type II antitoxins [52,70] when 513 
compared to the conditionally co-operative binding of TA complexes [28,52,71,72]. It is noteworthy 514 
that unlike many type II antitoxins, AbiEi and Rv2827c are fully folded and stable, and also no 515 
conditionally co-operative response was seen for AbiE, and so the conditional model proposed for 516 
many type II systems likely does not apply [15]. 517 
  518 
This study has shown that the similar structures and promoter architectures between AbiEi, Rv2827c 519 
(and indeed Rv1044) have been co-opted to form different regulatory modules. A greater 520 
understanding of how these nuances of regulation are applied in the cognate hosts may provide 521 
greater insight into the control of bacterial growth. Understanding these systems and how they 522 
regulate bacterial behaviour is thereby an important step in developing a means to control TA 523 
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Fig. 1. Antitoxin AbiEi is a two-domain protein with bilateral opposingly-charged faces. (A) Scaled 746 
representation of the four M. tuberculosis TA systems containing NTase-like toxin 747 
genes and AbiE from S. agalactiae. Numbers in parentheses indicate amino acid length. All 748 
five toxins are DUF1814 proteins; Rv1044, Rv2827c and AbiEi are COG5340-containing antitoxins. 749 
Putative antitoxin Rv0837c is a COG4861 protein and the significantly shorter putative antitoxin 750 
Rv0078B is unclassified. The four M. tuberculosis systems were re-named as shown. 751 
(B) AbiEi antitoxin structure shown in pink cartoon representation, in two views rotated 180°. (C) 752 
Electrostatic potential of AbiEi, posed as per (B), with electropositive charge in blue and 753 
electronegative charge in red. (D) Previously solved Rv2827c structure shown in blue cartoon 754 
representation, in two views rotated 180° (PDB: 1ZEL). (E) Electrostatic potential of Rv2827c, posed 755 
as per (D), colored as per (C). 756 
 757 
 758 
Fig. 2. AbiEi and Rv2827c are structurally similar, but have been captured in different positions with 759 
differing predicted protein interaction interfaces. (A) AbiEi (pink) and Rv2827c (blue) in cartoon 760 
representation, aligned via the N-terminal winged helix-turn-helix domains, shown as two 761 
orthogonal views. The positions of the C-terminal domains diverge at a 65º angle. (B) Close-up 762 
structural superposition of the isolated N-terminal helices of AbiEi and Rv2827c, colored as per (A). 763 
The three helices (H1-3) of the N-terminal winged helix-turn-helix domains align well. (C) Close-up 764 
structural superposition of the isolated C-terminal domains of AbiEi and Rv2827c, colored as per (A). 765 
The core secondary structural features of the C-terminal domains approximate to the same 766 
positions, but the Rv2827c C-terminal domain has additional features at the C-terminus. (D) 767 
AbiEi has C-terminal residues predicted to be involved in making protein-protein interactions, which 768 
might allow positive co-operativity in AbiEi monomer binding. AbiEi is in pink cartoon 769 
representation with identified interacting residues in red, and is shown in orthogonal views. (E) 770 
Rv2827c does not have an equivalent patch of C-terminal interacting residues. Rv2827c is in blue 771 
cartoon representation, with identified interacting residues in cyan, and is shown in 180° rotation. 772 
Residues were identified using the cons-PPISP server. Rv2827c PDB code: 1ZEL.   773 
 774 
 775 
Fig. 3. The rv2827c-rv2826c promoter has similar features but is more complex than 776 
the abiE promoter. (A) Cartoon of the abiE and rv2827c-rv2826c promoters (pink and blue, 777 
respectively), showing the relative positions of the 23 bp inverted repeats (IRs). Putative 778 
transcriptional -35, -10 and start sites, along with ribosome binding sites (RBS), are indicated where 779 
possible. (B) Alignment of the six, 23 bp, IR sequences shows consensus sequences between 780 
the abiE and rv2827c-rv2826c promoters. The alignment was made using MView and the consensus 781 
was made using WebLogo.  782 
 783 
Fig. 4. Rv2827c binds non-co-operatively to the IR3-IR4 region of the rv2827c-rv2826c promoter. (A) 784 
Sequence level cartoon of the fluorescently labelled probe containing IR3-IR4, with -35, -10 and 785 
transcriptional start indicated. (B) Electrophoretic mobility shift assay (EMSA) of titrated 786 
Rv2827c with the probe in (A). (C) EMSA of titrated Rv2827c with the probe in (A) altered by 787 
replacing IR4 with polyC. (D) EMSA of titrated Rv2827c with the probe in (A) altered by replacing IR3 788 




with polyC.  For (B-E); protein concentrations are shown on each panel together with the binding 790 
events (0, 1 or 2); S – each experiment contained 100-fold excess of the specific unlabelled probe; NS 791 
– each experiment contained 100-fold excess of non-specific unlabelled probe; numbering -1 to -71 792 
denotes the promoter region included in the probe, upstream of the translational start site in order 793 
to include all of IR4. (F) Fractional saturation curve plotted using the EMSA data of (B). (G) Hill plot 794 
using the EMSA data from (B). For (F) and (G), points are plotted from triplicate data and display 795 
mean values with standard error of the mean.  796 
 797 
Fig. 5. Rv2827c binds with weak negative co-operativity to the IR1-IR2 region of the rv2827c-798 
rv2826c promoter. (A) Sequence level cartoon of the fluorescently labelled probe containing IR1-IR2. 799 
(B) Electrophoretic mobility shift assay (EMSA) of titrated Rv2827c with the probe in (A). (C) EMSA of 800 
titrated Rv2827c with the probe in (A) altered by replacing IR2 with polyC. (D) EMSA of titrated 801 
Rv2827c with the probe in (A) altered by replacing IR1 with polyC. (E) EMSA of titrated Rv2827c with 802 
the probe in (A) altered by replacing both IR1 and IR2 with polyC.  For (B-E); protein concentrations 803 
are shown on each panel together with the binding events (0, 1 or 2); S – each experiment contained 804 
100-fold excess of the specific unlabelled probe; NS – each experiment contained 100-fold excess of 805 
non-specific unlabelled probe; numbering -60 to -131 denotes the promoter region included in the 806 
probe. (F) Fractional saturation curve plotted using the EMSA data of (B). (G) Hill plot using the EMSA 807 
data from (B). For (F) and (G), points are plotted from triplicate data and display mean values 808 
with standard error of the mean.  809 
 810 
Fig. 6. Rv2827c binds with negative co-operativity to the full rv2827c-rv2826c promoter. (A) EMSA of 811 
titrated Rv2827c with a probe covering from -1 to -131 of the rv2827c-rv2826c promoter, covering 812 
IR1 to IR4. The titration was performed across two EMSA gels, with an additional zero protein lane 813 
included in the second gel for normalization. Protein concentrations are shown below each gel 814 
together with the binding events (0, 1, 2, 3 or 4); S – each experiment contained 100-fold excess of 815 
the specific unlabelled probe; NS – each experiment contained 100-fold excess of non-specific 816 
unlabelled probe. (B) Fractional saturation curve plotted using the EMSA data of (A). (C) Hill plot 817 
using the EMSA data from (A). (D) Semi-log saturation curve plotted using the EMSA data of (A), 818 
showing distinct breaks in the binding curve, in accordance with the multiple binding sites contained 819 
in the probe. (E) Sequence level cartoon of the fluorescently labelled probe containing rv2827c-820 
rv2826c -1 to -131. (F-M) Saturation curves (F, H, J, L) and Hill plots (G, I, K, M) for each IR calculated 821 
using individual IR data gathered using mutant probes (Fig. 4C and D, Fig. 5C and D). For (B-D) and 822 
(F-M), points are plotted from triplicate data and display mean values with standard error of the 823 
mean.  824 
 825 
 826 
Fig. 7. Rv2827c-Rv2826c is a negatively autoregulating system in E. coli. (A) Promoter activity from 827 
upstream promoter regions of abiE (99 bp), and rv2827c-rv2826c and rv1044-rv1045 (500 bp for 828 
both) detected using lacZ transcriptional fusions. Both the abiE and rv2827c-rv2826c constructs are 829 
active, but the rv1044-rv1045 construct is not. Plotted data are normalized to the vector-only 830 
control. (B) Autoregulation of promoter activity by antitoxins. LacZ activity was measured from 831 
the abiE and rv2827c-rv2826c constructs with or without induction of the cognate antitoxin (AT, 832 
±IPTG). Both AbiE and Rv2827c negatively autoregulate expression. Plotted data are normalized to 833 
the uninduced vector-only control. All data (A-C) are plotted as the means of triplicate data, and 834 





Fig. 8. Proposed model for negative autoregulation caused by Rv2827c binding to the four rv2827c-837 
rv2826c promoter inverted repeats. (A) Schematic representation of the putative rv2827c-rv2826c 838 
type IV toxin-antitoxin system. Model shows both rv2827c and rv2826c being translated into the 839 
antagonistic antitoxin and toxin protein pair respectively. The antitoxin, Rv2827c has a second 840 
function and binds to the rv2827c-rv2826c promoter, negatively autoregulating the operon. (B) An 841 
order of binding is created by the distinct affinity values for the inverted repeats represented in the 842 
sequence level cartoon, calculated from individual IR data gathered using mutant probes (Fig. 4C and 843 
D, Fig. 5C and D). Rv2827c binds negatively co-operatively, initially to IR1 (0.0205 µM) followed by 844 




























Table 1. Crystallographic Data Collection and Refinement Statistics 







PDB ID Code 6Y8Q - - 
Number of crystals 3 2 1 
Beamline Diamond I03 Diamond I03 Diamond I03 
Wavelength, Å  0.9763 0.9793 0.9641 




42.58 – 2.14 
(2.19 – 2.14) 
53.57 – 2.17 
(2.23 – 2.17) 
Space group P1 P1 P1 
Unit cell, a b c (Å),    



















Unique reflections 106620 
(5213) 
69714 (4469) 65917 (4312) 
Multiplicity 1.9 6.4 2.0 
Completeness (%) 97.4 (96.1) 99.0 (97.1) 97.9 (91.9) 
Mean I/sigma(I) 7.6 6.9 6.1 
Rmerge 0.038 (0.691) 0.169 (1.036) 0.080 (0.593) 
Rmeas 0.053 (0.977) 0.184 (1.260) 0.113 (0.839) 







No. of non-hydrogen  
    atoms 
7116 - - 
    Macromolecules 6397 - - 
    Ligands 62 - - 
    Solvent 657 - - 
Protein Residues 769 - - 
RMSD (bonds, Å) 0.012 - - 
RMSD (angles, °) 1.32 - - 
Ramachandran   
    favored (%) 
98.68 - - 
Ramachandran 
    allowed (%) 
1.32 - - 
Ramachandran 
    outliers (%) 
0.00 - - 
Average B-factor 39.61 - - 
    Macromolecules 39.04 - - 
    Ligands 46.01 - - 























































SUPPLEMENTARY DATA 1 
 2 
Antitoxin autoregulation of M. tuberculosis toxin-antitoxin expression through 3 
negative cooperativity arising from multiple inverted repeat sequences 4 

















SUPPLEMENTARY FIGURES 19 
Fig. S1. AbiEi and Rv2827c have similar folds. Structure-based sequence alignment of AbiEi and 20 
Rv2827c, drawn by hand using output from PROMALS3D. Blue arrows represent β-sheets and pink 21 
ovals represent α-helices; numbers indicate amino acid positions.  22 
 23 
Fig. S2. AbiEi binds with positive co-operativity to the IR1-IR2 region of the abiE promoter. (A) 24 
Sequence level cartoon of the fluorescently labelled probe containing IR1-IR2, with -35, -10, 25 
transcriptional start and ribosome binding site (RBS) indicated. (B) Electrophoretic mobility shift assay 26 
(EMSA) of titrated AbiEi with the probe in (A). (C) EMSA of titrated AbiEi with the probe in (A) altered 27 
by replacing IR2 with polyC. (D) EMSA of titrated AbiEi with the probe in (A) altered by replacing IR1 28 
with polyC. (E) EMSA of titrated AbiEi with the probe in (A) altered by replacing both IR1 and IR2 29 
with polyC.  For (B-E); protein concentrations are shown on each panel together with the binding 30 
events (0, 1 or 2); S – each experiment contained 100-fold excess of the specific unlabelled probe; NS 31 
– each experiment contained 100-fold excess of non-specific unlabelled probe; numbering -1 to -71 32 
denotes the promoter region included in the probe, upstream of the translational start site in order 33 
to include all of IR2. (F) Fractional saturation curve plotted using the EMSA data of (B). (G) Hill plot 34 
using the EMSA data from (B). For (F) and (G), points are plotted from triplicate data and display mean 35 
values with standard error of the mean.  36 
 37 
Fig. S3. AbiEi and Rv2827c do not bind non-cognate promoters. (A) Electrophoretic mobility shift assay 38 
(EMSA) of titrated AbiEi with rv2827c-rv2826c promoter -1 to -71. (B) EMSA of 39 
titrated AbiEi with rv2827c-rv2826c promoter -61 to -131. (C) EMSA of titrated 40 
Rv2827c with abiE promoter -1 to -71. For (A-C); protein concentrations are shown below (C) together 41 
with the binding events (0, 1 or 2); S – each experiment contained 100-fold excess of the specific 42 
unlabelled probe; NS – each experiment contained 100-fold excess of non-specific unlabelled probe; 43 
numbering denotes the promoter region included in the probe, upstream of the translational start site 44 
in order to include all of the respective IR sequences.  45 
 46 
Fig. S4. Rv1044 does not bind the cognate promoter but is capable of DNA-binding. (A) EMSA of 47 
titrated Rv1044 with rv1044-rv1045 promoter -1 to -71. (B) EMSA of titrated Rv1044 with rv1044-48 
rv1045 promoter -61 to -131. (C) EMSA of titrated Rv1044 with rv2827c-rv2826c promoter -1 to -71. 49 
(D) EMSA of titrated Rv1044 with rv2827c-rv2826c promoter -61 to -131. (E) EMSA of titrated 50 
Rv1044 with abiE promoter -1 to -71. For (A-E); protein concentrations are shown on each panel 51 
together with the binding events (0, 1 or 2); S – each experiment contained 100-fold excess of the 52 
specific unlabelled probe; NS – each experiment contained 100-fold excess of non-specific unlabelled 53 
probe; numbering denotes the promoter region included in the probe, upstream of the translational 54 
start site in order to include all of the respective IR sequences. (F) Fractional saturation curve plotted 55 
using the EMSA data of (E). (G) Hill plot using the EMSA data from (E). For (F) and (G), points are plotted 56 






SUPPLEMENTARY TABLES 60 
˙Table S1. Oligonucleotides used in this study  




FWD EcoRI, 99 bp upstream of abiEi, 
S. agalactiae 
TRB1047 TTTAAGCTTTACGGCCCCCCACTTGTTGC REV HindIII, 99 bp upstream of abiEi, 
S. agalactiae 
TRB1042 TTTGAATTCGCCCAAGCATCGGCTGGC FWD EcoRI, 500 bp upstream of 
rv2827c, M. tuberculosis 
TRB1043 TTTAAGCTTCCGAACTTGAATTCACACCGG REV HindIII, 500 bp upstream of 
rv2827c, M. tuberculosis 
TRB1040 TTTGAATTCGGGTCCCAACCGAGCGGC FWD EcoRI, 500 bp upstream of 
rv1044, M. tuberculosis 
TRB1041 TTTAAGCTTATTAGGTGATGGAGGCCAAGGCC REV HindIII, 500 bp upstream of 
rv1044, M. tuberculosis 
   
pSAT1-LIC cloning 
TRB873 TTAATGCAGCTGATTAATACG FWD pSAT LIC sequencing 










REV abiEi LIC, S. agalactiae  
TRB1022 CAACAGCAGACGGGAGGTGTGAGCCCAGCCG
GCGCC  
FWD rv2827c LIC, M. tuberculosis 
TRB1023 GCGAGAACCAAGGAAAGGTTATTACGCCTTGC
CGATCACGCGCAGC 
REV rv2827c LIC, M. tuberculosis 
TRB1018 CAACAGCAGACGGGAGGTTGTGCAAAACCGT
ATCTAATTGATACGATTGCGC 
FWD rv1044 LIC, M. tuberculosis 
TRB1019 GCGAGAACCAAGGAAAGGTTATTACGCCGATG
CTCGCTTCGG 








FWD EcoRI, abiEi, S. agalactiae 
TRB1053 TTTAAGCTTGGTTATTATATTAGAACCTCCAGA
GTTTG 
REV HindIII, abiEi, S. agalactiae 
PF1334 TTTCATATGCAATTGAGGAGGACAGGGATGGT
GAGCCCAGCCG 
FWD NdeI/MfeI, rv2827c, M. 
tuberculosis 




FWD NdeI/MfeI, rv1044, M. 
tuberculosis 
PF1331 TTTACTAGTCCCGGGCTTGGTCACGCCGATG REV SpeI/XmaI, rv1044, M. 
tuberculosis 
   
EMSA probe primers and templates 
TRB1067 TGCGCACTGACAAAAGCTT REV EMSA untagged 
TRB1068 /56-FAM/TGCGCACTGACAAAAGCTT REV EMSA 56-FAM (fluorescein) 




S. agalactiae / abiEi -1 to -71 WT 
(Fig. S2B, Fig. S3C, Fig. S4E) 





S. agalactiae / abiEi -1 to -71 
Mutant; inverted repeat 1 poly-C 










S. agalactiae / abiEi -1 to -71 
Mutant; inverted repeat 2 poly-C 




S. agalactiae / abiEi -1 to -71 
Mutant; inverted repeat 1 & 2 poly-C 









M. tuberculosis H37Rv / rv1044, -1 to 
-71 WT (Fig. S4A) 







M. tuberculosis H37Rv / rv1044, -61 












M. tuberculosis H37Rv / rv2827c, -1 












M. tuberculosis H37Rv / rv2827c, -61 






FWD for TRB1106, TRB1277, full-





Plasmid pEFER, 12851-12920 bp NS 
probe (Fig. 4 – 6, Fig. S2 – S4)  






M. tuberculosis H37Rv / rv2827c, -1 
to -71 Mutant; inverted repeat 3 












M. tuberculosis H37Rv / rv2827c, -1 
to -71 Mutant; inverted repeat 4 






M. tuberculosis H37Rv / rv2827c, -1 
to -71 Mutant; inverted repeat 3 & 4 









M. tuberculosis H37Rv / rv2827c, -61 
to -131 Mutant; inverted repeat 1 





FWD for TRB1275, TRB1278, M. 






M. tuberculosis H37Rv / rv2827c, -61 
to -131 Mutant; inverted repeat 2 






M. tuberculosis H37Rv / rv2827c, -61 
to -131 Mutant; inverted repeat 1 & 
2 poly-C track substitution (Fig. 5E) 
aEMSA probe sequences are fused with a constant region from the lacZ gene of pRW50, highlighted in grey. The reverse 

















Table S2. Plasmids used in this study 














PF1334/PF1335 This work 
pRLD30 pTRB30-His6-
abiEi 
- - [15] 
pRW50 TcR - - [32] 
pSAT1-LIC ApR - - This work 
pTA100 SmR - - [5] 
pTRB481 pTA100-abiEi Restriction 
Cloning 
TRB1052/TRB1053 This work 





TRB1040/TRB1041 This work 





TRB1042/TRB1043 This work 






















TRB1048/TRB1049 This work 
 74 
 75 




